Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study

Project Oncology® - Un pódcast de ReachMD

Guest: Jorge Nieva, MD Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for home-based subcutaneous cancer therapies is Dr. Jorge Nivea. He’s an Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.

Visit the podcast's native language site